Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 07 October 2013 | By Alexander Gaffney, RAC,
EU and Japanese regulators are for the first time beginning to share good manufacturing practice (GMP) data between one another in limited cases, the European Medicines Agency (EMA) announced on Monday (7 October 2013).
At present, most global regulators receive data regarding not just the drug product for which a company seeks approval, but information on the way in which it will be manufactured as well. Regulators generally take that information and use it to assess the manufacturing facility's adherence to GMPs and if the product can be manufactured at scale.
But those inspections can end up being extremely repetitive, particularly for companies whose products are approved and marketed throughout the world. Focus has spoken with some industry regulatory officials who have reported having at least one inspection per month on average throughout some years.
In recognition of this challenge, some regulators have initiated discussion around so-called "mutual recognition agreements," or MRAs. In principle, the agreements allow a regulator to rely on the findings of another inspection regime (e.g. EMA relying on the US Food and Drug Administration), allowing them to have reasonable assurances of GMPs being followed. In addition, regulators are then able to inspect other facilities they might otherwise not have the regulatory capacity to get to.
Now EMA and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) have announced the expansion of its MRA with Japan to include GMP data "related to Japanese manufacturers upon the manufacturer's request."
The first EMA-PMDA MRA was put into effect in 2004, according to documents maintained on EMA's website, and the latest announcement serves to expand the existing MRA.
"It allows the EMA, European national competent authorities and Japanese authorities to use information in EudraGMDP instead of issuing original paper GMP certificates for a number of regulatory procedures, such as marketing authorisation applications or variation applications, including the addition of a new manufacturer," EMA wrote. "The EU and Japanese regulatory authorities will now accept a reference to a EudraGMDP entry, or a downloadable file or print-out from the database, within the scope of the EU-Japan MRA."
If the digital information is not accessible through the EudraGMDP system, paper copies may still be requested from members of industry, EMA added.
EMA Statement
Tags: Mutual Recognition Agreement, MRA, GMP, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.